Items Tagged ‘HER2-positive’

July 27th, 2016

Neratinib Improves Cancer-Free Survival in Early Breast Cancer

By

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

View full entry

Tags: Breast Cancer, early breast cancer, exteNET, HER2-positive, herceptin, neratinib, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, trastuzumab. her2


May 11th, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

By

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, herceptin, lapatinib, News, Rectal Cancer, trastuzumab, Tykerb


January 6th, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer who received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. […]

View full entry

Tags: antibody, Breast Cancer, Chemotherapy, combination therapy, HER2-positive, meastatic breast cancer, Metastatic Breast Cancer, News, T-DMI, TH3RESA trial, trastuzumab emtansine


January 3rd, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. and […]

View full entry

Tags: Breast Cancer, HER2-positive, metastatic, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, T-DMI, TH3RESA trial, trastuzumab emtansine